Gastroesophageal Reflux Disease – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of gastroesophageal reflux disease (GERD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan). We report the prevalence of GERD for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets.

Clarivate Epidemiology’s GERD forecast will answer the following questions:

• How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of GERD over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 16 GERD patient populations, including the following:

• Total prevalent cases of GERD by diagnosis scheme.
• Total prevalent cases of GERD by severity scheme.
• Total prevalent cases by Barrett’s esophagus scheme.
• Diagnosed prevalent cases of GERD by subtype.
• Diagnosed prevalent cases of GERD with erosive esophagitis by LA classification scheme.
• … and many more (details available on request).

Note: Coverage may vary by country.